177 related articles for article (PubMed ID: 22283863)
1. Soluble TWEAK and cardiovascular morbidity and mortality in chronic kidney disease patients.
Hassan SB; El-demery AB; Ahmed AI; Abukhalil RE
Arab J Nephrol Transplant; 2012 Jan; 5(1):27-32. PubMed ID: 22283863
[TBL] [Abstract][Full Text] [Related]
2. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients.
Carrero JJ; Ortiz A; Qureshi AR; Martín-Ventura JL; Bárány P; Heimbürger O; Marrón B; Metry G; Snaedal S; Lindholm B; Egido J; Stenvinkel P; Blanco-Colio LM
Clin J Am Soc Nephrol; 2009 Jan; 4(1):110-8. PubMed ID: 18945991
[TBL] [Abstract][Full Text] [Related]
3. Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.
Fernández-Laso V; Sastre C; Valdivielso JM; Betriu A; Fernández E; Egido J; Martín-Ventura JL; Blanco-Colio LM
Clin J Am Soc Nephrol; 2016 Mar; 11(3):413-22. PubMed ID: 26728587
[TBL] [Abstract][Full Text] [Related]
4. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.
Valdivielso JM; Coll B; Martín-Ventura JL; Moreno JA; Egido J; Fernández E; Blanco-Colio LM
J Nephrol; 2013; 26(6):1105-13. PubMed ID: 23475462
[TBL] [Abstract][Full Text] [Related]
5. Soluble TWEAK level: is it a marker for cardiovascular disease in long-term hemodialysis patients?
Gungor O; Kircelli F; Asci G; Carrero JJ; Tatar E; Demirci MS; Ozbek SS; Ceylan N; Toz H; Ozkahya M; Ok E
J Nephrol; 2013; 26(1):136-43. PubMed ID: 22505251
[TBL] [Abstract][Full Text] [Related]
6. Soluble tumor necrosis factor-like weak inducer of apoptosis plasma levels as a novel biomarker of endothelial function in prevalent orthotopic heart transplant recipients.
Przybylowski P; Malyszko JS; Malyszko J
Transplant Proc; 2011 Jun; 43(5):1900-3. PubMed ID: 21693297
[TBL] [Abstract][Full Text] [Related]
7. Intraindividual interleukin-6 variations on the cardiovascular prognosis of patients with chronic renal disease.
Goicoechea M; Quiroga B; García de Vinuesa S; Verdalles U; Reque J; Panizo N; Arroyo D; Santos A; Macías N; Luño J
Ren Fail; 2012; 34(8):1002-9. PubMed ID: 22746155
[TBL] [Abstract][Full Text] [Related]
8. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease.
Urbonaviciene G; Martin-Ventura JL; Lindholt JS; Urbonavicius S; Moreno JA; Egido J; Blanco-Colio LM
Atherosclerosis; 2011 Dec; 219(2):892-9. PubMed ID: 21962403
[TBL] [Abstract][Full Text] [Related]
9. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.
Yilmaz MI; Sonmez A; Ortiz A; Saglam M; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Çakar M; Egido J; Altun B; Yenicesu M; Blanco-Colio LM; Carrero JJ
Clin J Am Soc Nephrol; 2011 Apr; 6(4):785-92. PubMed ID: 21330486
[TBL] [Abstract][Full Text] [Related]
10. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.
Moreno JA; Dejouvencel T; Labreuche J; Smadja DM; Dussiot M; Martin-Ventura JL; Egido J; Gaussem P; Emmerich J; Michel JB; Blanco-Colio LM; Meilhac O
Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1253-62. PubMed ID: 20299688
[TBL] [Abstract][Full Text] [Related]
11. MCP-1 and soluble TWEAK levels are independently associated with coronary artery disease severity in patients with chronic kidney disease.
Akdoğan MF; Azak A; Denizli N; Huddam B; Koçak G; Gücün M; Tatlısu MA; Demirci R; Yılmaz B; Dikeç M; Bakırtaş M; Akdağ İ; Duranay M
Ren Fail; 2015; 37(8):1297-302. PubMed ID: 26382008
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion.
Brantsma AH; Bakker SJ; Hillege HL; de Zeeuw D; de Jong PE; Gansevoort RT;
Nephrol Dial Transplant; 2008 Dec; 23(12):3851-8. PubMed ID: 18641082
[TBL] [Abstract][Full Text] [Related]
13. Increased risk of mortality in the elderly population with late-stage chronic kidney disease: a cohort study in Taiwan.
Hwang SJ; Lin MY; Chen HC; Hwang SC; Yang WC; Hsu CC; Chiu HC; Mau LW
Nephrol Dial Transplant; 2008 Oct; 23(10):3192-8. PubMed ID: 18450830
[TBL] [Abstract][Full Text] [Related]
14. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease.
Yilmaz MI; Carrero JJ; Ortiz A; Martín-Ventura JL; Sonmez A; Saglam M; Yaman H; Yenicesu M; Egido J; Blanco-Colio LM
Clin J Am Soc Nephrol; 2009 Nov; 4(11):1716-23. PubMed ID: 19820131
[TBL] [Abstract][Full Text] [Related]
15. The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients.
Liabeuf S; Barreto DV; Barreto FC; Chasseraud M; Brazier M; Choukroun G; Kamel S; Massy ZA
Nephrol Dial Transplant; 2010 Aug; 25(8):2596-602. PubMed ID: 20190248
[TBL] [Abstract][Full Text] [Related]
16. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis.
Blanco-Colio LM; Martín-Ventura JL; Muñóz-García B; Orbe J; Páramo JA; Michel JB; Ortiz A; Meilhac O; Egido J
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):916-22. PubMed ID: 17272745
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of cardiovascular events and mortality among non-diabetic chronic kidney disease patients with hypertensive nephropathy: the Gonryo study.
Nakayama M; Sato T; Miyazaki M; Matsushima M; Sato H; Taguma Y; Ito S
Hypertens Res; 2011 Oct; 34(10):1106-10. PubMed ID: 21796127
[TBL] [Abstract][Full Text] [Related]
18. Elevated interleukin-12 and interleukin-18 in chronic kidney disease are not associated with arterial stiffness.
Yong K; Ooi EM; Dogra G; Mannion M; Boudville N; Chan D; Lim EM; Lim WH
Cytokine; 2013 Oct; 64(1):39-42. PubMed ID: 23778029
[TBL] [Abstract][Full Text] [Related]
19. Plasma cytokines, glomerular filtration rate and adipose tissue cytokines gene expression in chronic kidney disease (CKD) patients.
Spoto B; Leonardis D; Parlongo RM; Pizzini P; Pisano A; Cutrupi S; Testa A; Tripepi G; Zoccali C; Mallamaci F
Nutr Metab Cardiovasc Dis; 2012 Nov; 22(11):981-8. PubMed ID: 21906921
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of renal dysfunction in patients with inflammatory arthropathies: strong association with cardiovascular diseases and not with anti-rheumatic therapies, inflammatory markers or duration of arthritis.
Haroon M; Adeeb F; Devlin J; O Gradaigh D; Walker F
Int J Rheum Dis; 2011 Aug; 14(3):255-60. PubMed ID: 21816021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
